iBio price to sales ratio IBIO

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; a quarter missing
10-year median: 43.9×
10-year range: 1.6× to 197×
Peer median: 0.4×

iBio's price to sales ratio can't be checked today: its revenue for Q4 FY26, the quarter to Jun 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.

On the days it had one over the last ten years, its median was 43.9×, from 1.6× in Dec 2022 to 197× in May 2026.

Price to sales ratio over time

median 43.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	154×	90.8×	197×
2025	85.0×	23.4×	194×
2024	128×	79.9×	154×
2023	85.4×	2.2×	193×
2022	1.8×	1.6×	66.7×
2021	55.2×	55.2×	184×
2020	98.6×	3.5×	196×
2019	3.5×	1.7×	46.7×
2018	35.0×	15.1×	67.8×
2017	43.9×	36.5×	87.2×
2016	38.6×	33.7×	66.7×
2015	36.3×	27.6×	65.3×
2014	47.0×	36.6×	75.1×
2013	38.7×	16.3×	40.7×
2012	23.4×	23.4×	38.5×

Against its peers

Companies in Drug Manufacturers - General nearest iBio's size, closest first, today.

Company	Price to sales ratio
IBIOiBio	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on iBio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.